spacer
home > epc > autumn 2003 > colloidal gold nanoparticles as a new approach to target tumour necrosis factor to solid cancers
PUBLICATIONS
European Pharmaceutical Contractor

Colloidal Gold Nanoparticles as a New Approach to Target Tumour Necrosis Factor to Solid Cancers

Cancer remains a major threat to mankind, despite significant progress in the past decade in understanding, treating and preventing the disease. It is the second major cause of death in the Western world. In Europe, approximately 600,000 people died of cancer in 2000. In the US, cancer is responsible for almost 25 per cent of all deaths annually. In Table 1, current death rates for major cancers are presented. Of increasing concern is the expectation that cancer will continue to be an increasing burden on society, given the fact that the population is ageing and the incidence of cancer increases significantly in older individuals.

Managing and treating these deadly diseases comes at a significant cost to society. Approximately €17 billion was spent on drugs in 2001, divided among chemotherapy (50 per cent), hormonal treatment (35 per cent), and biologicals (15 per cent). The market for anti-cancer drugs is expected to grow at a double-digit rate in the next five years. With a number of promising biologicals recently approved and with advanced clinical trials, it is expected that the share of biologicals in this segment will increase significantly between now and 2008.

Given this highly unmet medical need, it is not surprising to find a large number of drugs in development aimed at treating cancer. According to a recent survey by the US Pharmaceutical Industry Association (PhRMA) there are approximately 175 biotechnology-derived drugs in clinical development for cancer by US companies. In another recent survey, the total number of cancer drugs in the preclinical and discovery pipeline is estimated to be over 500. Many of these are new drugs that work on newly identified targets and address previously unexplored pathways in an effort to more effectively treat these terribly debilitating diseases.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Gerben Moolhuizen MBA, Senior Manager Business Development and Leo de Leede PhD, Managing Director at OctoPlus, and Giulio Paciotti PhD, Co-Founder and Vice President for Research and Development, and Lawrence Tamarkin PhD Co-Founder, President and CEO of Cytimmune Sciences Inc

Gerben Moolhuizen, MBA, is Senior Manager Business Development at OctoPlus, a drug delivery and development company based in Leiden, The Netherlands. He has over 10 yearsХ experience in the entrepreneurial life sciences industry, both in project management and business development. Mr Moolhuizen obtained an MSc in Medical Biology from Utrecht University and an MBA from Erasmus University, Rotterdam School of Management.


Dr Leo de Leede PhD, is Managing Director of OctoPlus. He has over 20 years' experience in the pharmaceutical industry in various R&D functions at Organon (an Akzo-nobel division), Gist-brocades and Yamanouchi Europe, where he was Director Pre-Clinical Development for all European activities. Dr de Leede is Chairman of the Board of the Committee on Industrial Relations of the European Federation for Pharmaceutical Scientists. He studied Pharmacy and became a registered Pharmacist in 1979. He obtained a PhD in Biopharmaceutics from the University of Leiden.

Dr Giulio Paciotti PhD, is a Co-Founder and Vice President for Research and Development of CytImmune Sciences Inc. Dr Paciotti received his PhD from the University of Maryland, College Park, in the field of tumour biology. He established the company's research diagnostic division and currently heads the companyХs therapeutic efforts. He guided the development of Aurimune-TTM: a colloidal gold nanoparticle-based therapeutic that targets the delivery of TNF to solid tumours. Aurimune-TTM will be tested in a Phase I clinical trial later this year.


Dr Lawrence Tamarkin PhD, is the Co-Founder, President and CEO of CytImmune Sciences Inc, formed in 1988. In 1997, Dr Tamarkin re-focused the Company's resources to develop its patented, targeted drug delivery system, based on colloidal gold nanoparticles. This delivery system will harness the therapeutic potential of the potent but highly toxic anti-cancer biologic, tumour necrosis factor (TNF) by creating a colloidal gold TNF drug called Aurimune-TTM, which will enter clinical trial in 2003. Dr Tamarkin spent 12 years at the National Institutes of Health and conducted his PhD research at the University of Connecticut.



spacer
Gerben Moolhuizen
spacer
spacer
spacer
Dr Leo de Leede
spacer
spacer
spacer
Dr Giulio Paciotti
spacer
spacer
spacer
Dr Lawrence Tamarkin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Trial Supply West Coast Conference 2019

Philadelphia, USA – April 24, 2019. This year’s Clinical Trial Supply West Coast Conference will see leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) showcasing its specialist clinical trials expertise in relation to scheduled drugs.
More info >>

White Papers

Preparation of Pharmaceutical Samples for Metals Analysis

RSSL

There has been a lot of discussion regarding the methods of analysis for pharmaceutical products as we await the upcoming changes to both the EP and USP, relating to the analysis of metal impurities.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement